Article Details
Retrieved on: 2021-10-01 18:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NEW YORK – Gilead Sciences said this week that Health Canada has approved its antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for previously ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here